Current Developments for the Diagnosis and Treatment of Irritable Bowel Syndrome
Keywords: 5-HT; Bifidobacterium; Bifidobacterium strains; CNS; Crohn's disease; Dexamethasone; Gastroenterology; IB; IBS prevalence; IL-6; IL-8; Irritable bowel syndrome; Lactobacillus; Streptococcus; acetylcholine; antidepressants; antispasmodics; chemokines; cholecystokinin; chronic gastrointestinal disorder; cimetropium; clinical trials; corticotropin-releasing factor; dopamine; drug development; enteric nervous system; functional bowel disorders; gastrointestinal tract; immune modulation; inflammation; inflammatory bowel disease; interferon gamma; interleukin-6; lactose intolerance; macrolide; mebeverine; monoclonal antibodies; neurotransmitter; occludin; otilonium; pinaverium; polyethylene glycol; proteasomes; serotonin reuptake inhibitors; serotonin reuptake transporter; tegaserod; tricyclic antidepressants; tryptophan hydroxylase
Document Type: Research Article
Publication date: November 1, 2010
- Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.
Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites